<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226030</url>
  </required_header>
  <id_info>
    <org_study_id>PG-2008-2</org_study_id>
    <nct_id>NCT01226030</nct_id>
  </id_info>
  <brief_title>Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protgen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protgen Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is dose-escalation open-label study to determine the MTD of M2ES in Subjects With
      Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES
      will be selected to perform the pharmacokinetic study profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase I dose-escalation open-label study to determine the MTD of M2ES in
      Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and
      regimen of M2ES will be selected to perform the pharmacokinetic study profiles.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerate dosage</measure>
    <time_frame>4 weeks</time_frame>
    <description>The maxium tolerate dosage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) behavior of M2ES in tumor subject</measure>
    <time_frame>4 week</time_frame>
    <description>Pharmacokinetic (PK) behavior of different doses of M2ES in Subjects With Advanced Solid Tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of adverse event</measure>
    <time_frame>4 weeks</time_frame>
    <description>The incidence rate of adverse event</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>M2ES 7.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M2ES 7.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M2ES 15mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M2ES 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M2ES 60mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 7.5mg</intervention_name>
    <description>M2ES 7.5mg</description>
    <arm_group_label>M2ES 7.5mg</arm_group_label>
    <other_name>M2ES 7.5mg IV D1,8,15,22, every 28days a cycle.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 15mg</intervention_name>
    <description>M2ES 15mg</description>
    <arm_group_label>M2ES 15mg</arm_group_label>
    <other_name>M2ES 15mg IV D1,8,15,22, every 28days a cycle.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 30mg</intervention_name>
    <description>M2ES 30mg</description>
    <arm_group_label>M2ES 30mg</arm_group_label>
    <other_name>M2ES 30mg IV D1,8,15,22, every 28days a cycle.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 60mg</intervention_name>
    <description>M2ES 60mg</description>
    <arm_group_label>M2ES 60mg</arm_group_label>
    <other_name>M2ES 60mg IV D1,8,15,22, every 28days a cycle.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 60 years of age

          2. patients had histologically or cytologically confirmed solid tumors that was
             refractory to standard therapy.

          3. life expectancy of at least 3 months.

          4. ECOGPS ≤ 1

          5. Adequate hematologic, renal, and hepatic function was required as determined by the
             following: WBC ≥4×109/L, absolute neutrophil count ≥ 1.5×109/L, platelet count
             ≥100×109/L, hemoglobin ≥ 9g/dL, total bilirubin ≤1.5 upper limit of normal [ULN],AST ≤
             2.5 ULN, or ≤ 5 ULN if there was evidence of liver metastases; alkaline phosphatase ≤
             2.5 ULN, or ≤ 5 ULN if there was evidence of liver Metastases; creatinine clearance
             ≥50 mL/min.

        Exclusion Criteria:

          1. Pregnant and latent women, no contraception for women of childbearing age

          2. Have taken other treatments

          3. Be allergic to endostatin and other ingredient

          4. Gastrointestinal Hemorrhage

          5. Have Participated any clinical trail during the last 4 week

          6. ECG: QTC ≥ 480 ms

          7. patients had clinically apparent CNS disease ( primary brain tumors, tumor related
             apoplexy, CNS metastases, carcinomatous meningitis.)

          8. Cardiovascular and mental disease

          9. HIV-1 infected

         10. HBV, HBV infected ,Hepatitis B surface antigen positive

         11. Patients on therapeutic doses of heparin or antiplatelet agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Su LI, PhD</last_name>
    <phone>8620-87343571</phone>
    <email>lisusu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Li, PhD</last_name>
      <phone>8620-87343571</phone>
      <email>lisusu@126.com</email>
    </contact>
    <investigator>
      <last_name>LI Zhang, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>October 20, 2010</last_update_submitted>
  <last_update_submitted_qc>October 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Guodong Chang</name_title>
    <organization>Protgen Ltd</organization>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

